-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients With Lung Cancer
The COVID-19 pandemic has caused more than 43.2 million cumulative cases and 1.16 million deaths, as of late October 2020. Approximately 1% of patients with COVID-19 have malignancy,1 and lung cancer accounts for a considerable portion of these malignancies. Patients with lung cancer have often experienced severe disease when they contract COVID-19,2 which highlights the…
-
EGFR/ALK-Mutated NSCLC: Using Real-world Therapeutic Practices to Help Answer Real-world Therapeutic Questions
ILCN Editorial Group member Shirish M. Gadgeel, MD, is Chief of the Division of Hematology/Oncology at the Henry Ford Cancer Institute/Henry Ford Hospital. Dr. Gadgeel is currently working, in conjunction with four other institutions, on a phase II study evaluating pembrolizumab plus chemotherapy in patients with EGFR mutation positive and ALK translocated NSCLC previously treated…
-
SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?
Surgery is considered the preferred treatment in patients with lung cancer who are fit to undergo the procedure. Stereotactic radiotherapy (SBRT) is guideline recommended for patients who are unfit for surgery or who decline to undergo the procedure. The ongoing debate about the role of SBRT in fit patients reflects the absence of data from…
-
Increasing Understanding about the Role Biosimilar Agents in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 1 of 2)
In September 2017, the FDA approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename agent. Although bevacizumab-awwb is the only biosimilar agent specific to lung cancer, there are many others in development. Gary Lyman, MD, is Professor of Public Health Sciences and Clinical Research at the Fred Hutchinson Cancer Research…
-
Osimertinib Approved as Adjuvant Therapy for NSCLC with Certain EGFR Mutations
December 18, 2020—The U.S. Food and Drug Administration (FDA) approved osimertinib as post-resection adjuvant therapy for patients with NSCLC and EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ADAURA randomly assigned (1:1) 682 patients who had undergone surgery to 80 mg of oral osimertinib daily or to placebo…
-
Leora Horn, MD, MSc, FRCPC
Leora Horn, MD, MSc, FRCPC, has joined AstraZeneca as the Global Head of Lung Cancer Strategy. Prior to joining AstraZeneca in September 2020, Dr. Horn was an Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Associate Professor of Medicine in the Division of Hematology/Oncology at the Vanderbilt University Medical Center.
-
Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Associate Professor of Nursing at Yale University, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, added Fellow of the American Academy of Nursing (FAAN) to her impressive list of awards and credentials. The fellowship is one of the highest honors a nurse can be invited to apply for and, Ms. Davies was officially…
-
Interstitial Lung Abnormality, Interstitial Lung Disease, and Lung Cancer
As a practicing chest radiologist in Boston, one of this article’s authors (Dr. Hatabu) encounters several patients with drug-related pneumonitis (DRP) daily when on clinical duty. Sometimes DRP coexists with COVID-19 pneumonia or radiation pneumonitis. Recently, clinicians have begun to notice the increased incidence of DRP associated with molecular targeted therapy and immunotherapy in patients…
-
Alexander Drilon, MD
Alexander Drilon, MD, is now Memorial Sloan Kettering Cancer Center’s Chief of the Early Drug Development (EDD) Service in the Division of Solid Tumor Oncology of the Department of Medicine. In this role, Dr. Drilon oversees early-phase solid tumor drug development. The EDD has an extensive portfolio of molecularly-directed, immunomodulatory and other novel systemic therapies.…
-
Pembrolizumab Is Active in Lung Cancer Brain Metastases
In Reference To: Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5)655-663. Many studies over the past several years have clearly demonstrated the efficacy of PD-1 and PD-L1 inhibitors for NSCLC,…
View ILCN Archives
Provider Resources
Popular Articles